Trial reportNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2013
Impact of frequent hemodialysis on anemia management: results from the Frequent Hemodialysis Network (FHN) Trials.
Trial report in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Interventions for fatigue in people with kidney failure requiring dialysis.The Cochrane database of systematic reviews · 2023Pooled it
- Home versus in-centre haemodialysis for end-stage kidney disease.The Cochrane database of systematic reviews · 2014Pooled it
- Long-Term Effects of Frequent In-Center Hemodialysis.Journal of the American Society of Nephrology : JASN · 2016Trial
- Long-term Effects of Frequent Nocturnal Hemodialysis on Mortality: The Frequent Hemodialysis Network (FHN) Nocturnal Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2015Trial
- The cardiovascular unphysiology of thrice weekly hemodialysis.Current opinion in nephrology and hypertension · 2025Review
- Patient Survival With Extended Home Hemodialysis Compared to In-Center Conventional Hemodialysis.Kidney international reports · 2023Article
- A multicenter descriptive analysis of anemia management in hemodialysis patients and its association with quality of life.BMC nephrology · 2023Article
- Nocturnal hemodialysis: improved quality of life and patient outcomes.International journal of nephrology and renovascular disease · 2019Review
- Frequent hemodialysis: history of the modality and assessment of outcomes.Pediatric nephrology (Berlin, Germany) · 2017Article
- Chronic Hemodialysis Therapy in the West.Kidney diseases (Basel, Switzerland) · 2015Review
- Kt/V (and especially its modifications) remains a useful measure of hemodialysis dose.Kidney international · 2015Review
- The changing landscape of home dialysis in the United States.Current opinion in nephrology and hypertension · 2014Review
- Caregiver burden and hemodialysis.Clinical journal of the American Society of Nephrology : CJASN · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe extent to which anemia management is facilitated by more frequent hemodialysis (HD) is controversial. We hypothesized as a preselected outcome that patients receiving HD six times (6×) compared with three times (3×) per week would require lower doses of erythropoietin-stimulating agents (ESA) and/or achieve higher blood hemoglobin (Hb) concentrations.
methodsSubjects enrolled in the Frequent Hemodialysis Network (FHN) daily and nocturnal trials were studied. As the primary outcome for anemia, the dose of ESAs was recorded at 4-month intervals and the monthly dose of intravenous iron (IV Fe) was reported. Serum iron, transferrin saturation and ferritin were measured at baseline and then at 4-month intervals, whereas Hb concentration was measured monthly.
resultsThere was no significant treatment effect in the 6× versus 3× treatment groups on logESA dose or the ratio of log of ESA dose to Hb concentration in either trial. In the daily trial, Hb concentrations increased significantly in the 6× versus 3× group, at Month 12 compared with baseline (0.3 g/dL; 95% CI: 0.05-0.58, P<0.021), but both groups had Hb concentrations in the usual target range. In the daily trial, the weekly logESA dose and the logESA dose to Hb concentration ratio tended to decline more in the 6× versus 3× group. This trend was not observed in the nocturnal trial. IV Fe doses were significantly lower in the 6× compared with the 3× group by Month 12 in the nocturnal trial, but not different in the daily trial.
conclusionsIn the FHN Daily and Nocturnal Trials, more frequent HD did not have a significant or clinically important effect on anemia management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.